CorMedix · Nasdaq: CRMD · DefenCath (taurolidine and heparin)
DefenCath after the FDA's letters: the record, reconstructed.
2 FDA letters on NDA 214520, read alongside CorMedix's SEC filings. What changed after each FDA decision, in 9 questions answered from 20 source documents.
Quotes an FDA letterQuotes a company filingA line joins two questions whose answers quote the same passage. Hover a question to trace it.
FDA action or letterCompany filingHover a question to see which others share its evidence
Feb – Apr 2021
First Complete Response Letter
May 2021 – Mar 2022
Remediation and resubmission
Aug 2022
Second Complete Response Letter
Nov 2022 – Sep 2023
Three manufacturing pathways and a Type A meeting
2024 – 2026
Launch and litigation
2021 – 2026
Across the record
Questions that span the whole record rather than one period
Cross-investigations involving CorMedix
Questions that connect CorMedix's record with other companies'.
- What happens after a second FDA Complete Response Letter?Divergent outcome · with Aldeyra Therapeutics · Outlook Therapeutics · Replimune · Verrica Pharmaceuticals
- What is a Class 1 or Class 2 resubmission, and how did each play out in these records?Regulatory pathway · with Aldeyra Therapeutics · Outlook Therapeutics · Replimune
- What happens when an FDA letter turns on a contract manufacturer, not the drug?Shared concern · with Verrica Pharmaceuticals
- What did “no efficacy or safety issues” cover in these FDA letter announcements?Shared concern · with Replimune · Verrica Pharmaceuticals
Prepared from public FDA letters and SEC filings: every quoted passage is matched to the original document, and every “not in” statement comes from a search of the whole document, before it is published. Questions, summaries and connecting sentences are EphemerisX’s wording. Not investment advice. How this research works → · Ask the FDA and SEC Ephemeris →